Article
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Cell cycle (Georgetown, Tex.) - 15 Jan 2011
Hochhaus Andreas, La Rosée Paul, Müller Martin C, Ernst Thomas, Cross Nicholas C P
Abstract excerpt
Therapies that target BCR-ABL in chronic myeloid leukemia, including imatinib, dasatinib and nilotinib, have dramatically improved patient outcome. BCR-ABL mutations, however, contribute to treatment resistance by disrupting drug contact sites or causing conformational changes thus making contact sites inaccessible. Clinical data indicate that developing BCR-ABL mutations during imatinib treatment is predictive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.